Sponsor Deadline
Posted: 4/18/2022

Trans-Agency Blood-Brain Interface Program (R61/R33 - Clinical Trials Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support high risk/high reward research on the blood/vascular component and regulation of the neurovascular-blood unit (a.k.a., Blood-Brain Barrier; BBB) in normal and pathological states to create enhanced/modified platforms that more closely model the human BBB. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell interaction across the Blood-Brain Interface is of particular interest. This initiative will serve to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to develop the next generation of pre-clinical human cellular model systems of the human BBB to complement research currently based on animal models.

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): December 2, 2019, Dec. 11, 2020 (per NOT-HL-20-813.)
  • AIDS Application Due Date(s): December 17, 2019, December 21, 2020

​RFA-HL-20-021 Expiration Date December 22, 2020

Eligibility Requirements

Multi-PD/PI applications are required in response to this FOA. The research leadership team (Multi-PI PD/PI) must be comprised of experienced PDs/PIs with complementary multidisciplinary expertise for the multifaceted problems of the Blood-Brain Barrier field. If appropriate, early stage investigators or junior faculty may be included as co-investigators. The application must propose a multidisciplinary team that includes at least one team member with demonstrated expertise in blood science. Applications that do not propose a Multi-PD/PI team will be considered non-compliant and will not proceed to peer review.

Amount Description

Application budgets are limited to $425,000 direct costs per year.

The total project period request may not exceed 5 years.

Amount
$2,125,000
Funding Type
Eligibility
Posted
4/18/2022
Deadline
Sponsor: